This grant supports activities advancing the development of new small molecule antiviral therapeutics for emerging or re-emerging viral infections with epidemic or pandemic potential. The goal is to better prepare Europe and the world for future health threats by providing experimental antivirals for clinical investigation and patient treatment, strengthening research and innovation in the EU, and supporting the European Medical Countermeasures Strategy. The grant encourages the participation of start-ups and SMEs and requires close engagement with regulatory bodies. Projects must target specific viruses or groups of viruses and may include drug discovery, optimisation, in vitro and in vivo studies, manufacturing under GMP, and early clinical trials. Antibodies and antibody-derived proteins are excluded.
| Agency | HORIZON (EU) |
|---|---|
| Region | EU |
| Country | N/A |
| Legal form | Company, NGO, Government organization, Other |
| Start date | 10 Feb 2027 |
| End date | 13 Apr 2027 |
| Max funding | €9,000,000–€11,000,000 per grant |
| Budget | €44,200,000 overall budget allocated to this topic for 2027 |
| Coverage | EU funding for eligible costs as per Horizon Europe terms. US legal entities are eligible for funding. Funding rules follow Horizon Europe Model Grant Agreement. |